Zai Lab (ZLAB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting opened by the Chairperson, welcoming shareholders both in person and virtually, ensuring equal participation rights.
Inspector of Elections and Chief Legal Officer introduced to oversee proceedings and formalities.
Notice of meeting and proxy statement confirmed as duly distributed to all shareholders of record.
Shareholder proposals
Fourteen items of business presented for voting, including director reelections, auditor appointments, executive compensation, and share issuance/repurchase mandates.
No written questions were received from shareholders in advance of the meeting.
Board and executive committee updates
Nine directors proposed for reelection to serve until the 2027 AGM or until successors are elected.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zai Lab
- Q1 2026 revenue fell 6% YoY to $99.6M; pipeline and launches support future growth.ZLAB
Q1 20267 May 2026 - Key votes include director re-elections, auditor approval, and share issuance/repurchase mandates.ZLAB
Proxy filing28 Apr 2026 - Proxy covers director elections, auditor appointments, compensation, share mandates, and ESG strategy.ZLAB
Proxy filing28 Apr 2026 - Strong intracranial and systemic efficacy with favorable safety in SCLC and neuroendocrine tumors.ZLAB
Study update21 Apr 2026 - Shareholders will vote on director re-elections, auditor appointments, compensation, and share mandates.ZLAB
Proxy filing17 Apr 2026 - 2025 revenue up 15% to $460.2M, net loss narrowed, and pipeline advances set up 2026 milestones.ZLAB
Q4 202526 Feb 2026 - Global pipeline advances with DLL3 ADC phase III, new ADCs, and immunotherapies entering clinic.ZLAB
Citi’s 2026 Virtual Oncology Leadership Summit23 Feb 2026 - Strong VYVGART launch, pipeline expansion, and solid cash position drive growth and profitability.ZLAB
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Q2 2024 revenue up 45% to $100.1M, net loss narrows, VYVGART guidance raised above $80M.ZLAB
Q2 20242 Feb 2026